Get the Stockscreener App
0.00
100.00%
-0.0129
Nls Pharmaceutics Ag stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.
See More
Previous Close:
$0.0129
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.0164
52-Week Range:
$0.00
$0.0698
Nls Pharmaceutics Ag Stock (NLSPW) Company Profile
Name
Nls Pharmaceutics Ag
Sector
Industry
Phone
41 44 512 21 50
Address
The Circle 6, Zurich
Compare NLSPW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NLSPW
Nls Pharmaceutics Ag
|
0.00 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Nls Pharmaceutics Ag Stock (NLSPW) Latest News
NLS Pharmaceutics secures $2M for Kadimastem merger - Investing.com
NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement - StreetInsider.com
NLSP stock touches 52-week low at $1.47 amid market challenges By Investing.com - Investing.com South Africa
NLSP stock touches 52-week low at $1.47 amid market challenges - Investing.com India
NLS Pharmaceutics Ltd. (NASDAQ:NLSPW) Short Interest Down 31.6% in February - Defense World
NLS Pharmaceutics announces merger with Kadimastem - Investing.com India
NLS Pharmaceutics announces merger with Kadimastem By Investing.com - Investing.com UK
NLS Pharmaceutics CEO Issues Letter to Shareholders - Yahoo Finance
Pre-market Movers: PRFX, BJDX, TARA, PBM... - RTTNews
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger - Marketscreener.com
NLSP stock touches 52-week low at $1.71 amid steep annual decline By Investing.com - Investing.com South Africa
NLSP stock touches 52-week low at $1.71 amid steep annual decline - Investing.com India
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq - accessnewswire.com
NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement - ACCESS Newswire
AEX-2 increases total wake duration in mouse model - BioWorld Online
NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment - ACCESS Newswire
NLS Pharmaceutics reports progress in narcolepsy treatment By Investing.com - Investing.com South Africa
NLS Pharmaceutics reports progress in narcolepsy treatment - Investing.com
Pre-IND meeting guides path forward for ITOL-102 for type 1 diabetes - BioWorld Online
NLS Pharmaceutics and Partners Achieve Milestone in Diabetes Treatment Development - MSN
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment - Yahoo Finance
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder - ACCESS Newswire
NLS Pharmaceutics And Kadimastem Unveil Multi-Target Diabetes Approach - Nasdaq
Is NLSP’s price to cash per share ratio a concern for investors? - US Post News
NLS Pharmaceutics (NLSP) Shares Surge As Market Reacts To Potential Merger - Stocks Telegraph
NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies - Marketscreener.com
Pre-market Movers: PALI, KROS, AVGR, TRVI... - RTTNews
Pre-market Movers: SLGL, VIRX, ANVS, CUTR... - RTTNews
NLS Pharmaceutics to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference - ACCESS Newswire
Dow Edges Lower; Exxon Mobil Earnings Top Views - Benzinga
NLS Pharmaceutics Says Kadimastem Shareholders Approve Merger With NLS; Shares Rise - Marketscreener.com
Nasdaq Jumps Over 150 Points; Apple Posts Upbeat Earnings - Benzinga India
NLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice - ACCESS Newswire
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics -January 31, 2025 at 07:31 am EST - Marketscreener.com
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements - ACCESS Newswire
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence - Marketscreener.com
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence - Benzinga
NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions - ACCESS Newswire
NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment - ACCESS Newswire
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance - ACCESS Newswire
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing - ACCESS Newswire
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform - ACCESS Newswire
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence - ACCESS Newswire
NLS Pharmaceutics Announces Company Update on Strategic Partnerships - ACCESS Newswire
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - ACCESS Newswire
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering - ACCESS Newswire
NLSP Stock Touches 52-Week Low at $1.73 Amid Steep Annual Decline - MSN
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split - ACCESS Newswire
NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge - ACCESS Newswire
Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS - Marketscreener.com
SEC Form 425 filed by NLS Pharmaceutics Ltd. - Quantisnow
Nls Pharmaceutics Ag Stock (NLSPW) Financials Data
There is no financial data for Nls Pharmaceutics Ag (NLSPW). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.00%
Cap:
|
Volume (24h):